These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 16978155

  • 1. Determination of structurally conservative amino acids of the HIV-1 protein gp120 V3 loop as promising targets for drug design by protein engineering approaches.
    Andrianov AM, Veresov VG.
    Biochemistry (Mosc); 2006 Aug; 71(8):906-14. PubMed ID: 16978155
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.
    Andrianov AM, Veresov VG.
    J Biomol Struct Dyn; 2007 Jun; 24(6):597-608. PubMed ID: 17508782
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O, Chill J, Sharon M, Kessler N, Mester B, Zolla-Pazner S, Anglister J.
    Biochemistry; 2005 May 17; 44(19):7250-8. PubMed ID: 15882063
    [Abstract] [Full Text] [Related]

  • 8. Conformational preferences of the HIV-1 principal neutralizing determinant.
    Andrianov AM.
    J Biomol Struct Dyn; 2005 Dec 17; 23(3):267-82. PubMed ID: 16218754
    [Abstract] [Full Text] [Related]

  • 9. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM, de Lorimier R, Moody MA, Haynes BF, Spicer LD.
    Biochemistry; 1996 Apr 23; 35(16):5158-65. PubMed ID: 8611499
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
    Andrianov AM, Anishchenko IV, Tuzikov AV.
    J Chem Inf Model; 2011 Oct 24; 51(10):2760-7. PubMed ID: 21888425
    [Abstract] [Full Text] [Related]

  • 11. Local structural properties of the V3 loop of Thailand HIV-1 isolate.
    Andrianov AM.
    J Biomol Struct Dyn; 2002 Jun 24; 19(6):973-89. PubMed ID: 12023800
    [Abstract] [Full Text] [Related]

  • 12. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Jun 24; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype.
    Bhattacharyya D, Brooks BR, Callahan L.
    AIDS Res Hum Retroviruses; 1996 Jan 20; 12(2):83-90. PubMed ID: 8834457
    [Abstract] [Full Text] [Related]

  • 15. Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe.
    Andrianov AM, Kornoushenko YV, Anishchenko IV, Eremin VF, Tuzikov AV.
    J Biomol Struct Dyn; 2013 Jan 20; 31(7):665-83. PubMed ID: 22888999
    [Abstract] [Full Text] [Related]

  • 16. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations.
    Ebenbichler C, Westervelt P, Carrillo A, Henkel T, Johnson D, Ratner L.
    AIDS; 1993 May 20; 7(5):639-46. PubMed ID: 7686374
    [Abstract] [Full Text] [Related]

  • 17. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
    Huisman JG, Carotenuto A, Labrijn AF, Papavoine CH, Laman JD, Schellekens MM, Koppelman MH, Hilbers CW.
    Biochemistry; 2000 Sep 05; 39(35):10866-76. PubMed ID: 10978173
    [Abstract] [Full Text] [Related]

  • 18. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A, Feigelson DJ, Hayek Y, Anglister J.
    Biochemistry; 1997 Jul 15; 36(28):8619-27. PubMed ID: 9214308
    [Abstract] [Full Text] [Related]

  • 19. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
    Andrianov AM, Kornoushenko YV, Kashyn IA, Kisel MA, Tuzikov AV.
    J Biomol Struct Dyn; 2015 Jul 15; 33(5):1051-66. PubMed ID: 24942968
    [Abstract] [Full Text] [Related]

  • 20. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion.
    Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J.
    Proc Natl Acad Sci U S A; 2006 Sep 19; 103(38):13950-5. PubMed ID: 16966601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.